Spinal Muscular Atrophy drug: regulatory approval should guide Kerala’s procurement policy, say experts
Kerala is debating whether to switch from a high-priced patented drug to a significantly cheaper generic version for treating Spinal Muscular Atrophy. While the government aims to expand access, patient advocacy groups are concerned about the clinical efficacy of the generic alternative.
Why it matters
This case illustrates the complex balance between public health budget constraints and the rigorous safety standards required for rare disease treatments.
The treatment of Spinal Muscular Atrophy (SMA), a rare progressive genetic disorder that destroys motor neurons and weakens muscles, leading to severe disability and sometimes, premature death, is emerging as a contentious issue in Kerala.
The article presents both the government's fiscal perspective and the patient advocacy group's safety concerns fairly.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in